Upcoming Login Downtime
We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.
For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | May 28, 2020
Distillery Therapeutics
microRNA cluster identified as targets for ischemic stroke
BioCentury | May 17, 2018
Finance
Europe’s piece of the pie
Where European life science innovators can take the lead
BioCentury | Aug 17, 2017
Targets & Mechanisms
GRP-THINK AT THE BBB
How anti-GRP78 antibodies could help therapeutic mAbs get through the BBB
BioCentury | Jul 26, 2017
Emerging Company Profile
Breaching the gates
How Junction is using siRNAs to transiently breach the blood-brain barrier
BioCentury | Oct 1, 2015
Distillery Therapeutics
Therapeutics: Claudin 5 (CLDN5); occludin (OCLN); β amyloid (Aβ)
Items per page:
1 - 10 of 15